March 2026 Seminar Presenters

Amna Aurang Zaib

Program:

Biochemistry and Molecular Biology


Presentation Topic:

Identifying LLGL2 as a critical regulator of cell division, genomic stability, and glutamatergic signaling


Bio:

Amna Aurang Zaib is a fifth-year graduate student at the University of Maryland, Baltimore. Her research work integrates cerebral organoid, zebrafish and mouse models to study the impact of gene dysfunction on the developing brain. She is currently leveraging this background to transition into the field of neurodegeneration through the development of iPSC-based system.

Title: LLGL2 protein participates in the brain development and cognitive function, likely through regulation of glutamate neurotransmission

LLGL2 (MIM: 618483) encodes the Lethal giant larvae 2 protein, a key regulator of cell polarity, asymmetric division, and migration. In this study, we identified eight affected individuals from four unrelated families harboring one splicing and three missense variants in LLGL2 that segregate with neurodevelopmental disorder (NDD), epilepsy, and microcephaly. Overexpression of constructs carrying NDD-associated variants altered the subcellular localization of LLGL2 and disrupted cytoskeletal organization. Using homology-directed repair (HDR)-mediated CRISPR-Cas9 genome editing, we introduced the c.1456G>A variant into HEK293T cells. The knock-in cells exhibited pronounced mitotic defects, including aberrant centrosome assembly, multipolar spindle formation, increased multinucleation, and abnormal cytokinesis, along with altered centrosome number and diameter. These cells also displayed a significant increase in γ-H2AX foci, indicative of elevated DNA damage, and a reduced proliferation rate. Flow cytometric profiling revealed marked perturbations across all phases of the cell cycle.


Bulk mRNA sequencing of knock-in cells demonstrated significant dysregulation of the glutamatergic pathway and ERK1/2 regulatory networks—key modulators of excitatory neurotransmission and higher-order brain functions such as cognition and behavior. Further, to investigate LLGL2 function in vivo, we generated llgl2 knockdown zebrafish larvae. Consistent with the human phenotype, llgl2 morphants exhibited developmental abnormalities and reduced locomotor activity, both of which were rescued by co-injection of human wild-type LLGL2 mRNA but not mRNAs harboring NDD variants, confirming their pathogenicity. Parallel studies using c.1456G>A knock-in human induced pluripotent stem cells (iPSCs) revealed altered neural progenitor cell (NPC) morphology, including changes in embryoid body diameter and shape, and an accelerated differentiation potential relative to controls. Ongoing work using cortical neurons derived from these NPCs aims to delineate the impact of LLGL2 mutation on neuronal morphology and glutamatergic function. In summary, our findings establish LLGL2 as a critical regulator of cell division, genomic stability, and glutamatergic signaling, and highlight its essential role in human neurodevelopment and cognitive function.

Sudeep Khadka

Program: 

Biochemistry and Molecular Biology


Presentation Topic:

JMJD1A–EZH2 Axis as an Epigenetic Driver and Therapeutic Target in Castration-Resistant Prostate Cancer


Bio:

As a biochemistry and molecular biology Ph.D. candidate at UMB (joined 2021), I investigate the epigenetic mechanisms of prostate cancer progression, specifically focusing on how the interaction between JMJD1A and EZH2 co-regulates therapy resistance.

Title: JMJD1A–EZH2 Axis as an Epigenetic Driver and Therapeutic Target in Castration-Resistant Prostate Cancer

The histone demethylase JMJD1A (KDM3A) regulates chromatin dynamics by erasing the repressive H3K9me2 mark, thereby activating gene expression programs such as androgen receptor (AR) signaling that drive prostate cancer progression. EZH2, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), canonically acts as a transcriptional repressor through H3K27me3 deposition. While this paradigm underlies current therapeutic strategies targeting EZH2, emerging evidence shows that EZH2 also functions as a non-canonical transcriptional activator in prostate cancer, though the mechanisms remain poorly understood. This study investigates how JMJD1A regulates this transcription-activating role of EZH2. Using ChIP-seq, we mapped the chromatin occupancy of JMJD1A and EZH2 and identified their enrichment at sites marked by active histone modifications highlighting the non-canonical transcriptional activator function. RNA-seq and functional assays revealed that E2F1 and AR are key transcriptional outputs of the JMJD1A–EZH2 axis. Functionally, JMJD1A and EZH2 cooperatively promote E2F1-driven cell cycle progression and enhance AR activity, thereby accelerating castration-resistant prostate cancer (CRPC) progression. Mechanistically, JMJD1A stabilizes EZH2 and recruits it, along with the histone acetyltransferase p300, to AR- and E2F1-target genes, reprogramming EZH2 from a repressor into a co-activator of transcription. Collectively, these findings uncover a novel mechanism by which JMJD1A drives the non-canonical co-activator function of EZH2 and establish the JMJD1A-EZH2 axis as a critical epigenetic driver and promising therapeutic target in advanced prostate cancer.